We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
76
iRhythm Holdings
IRTC
$3.66B
$2.1M 0.21%
33,400
– –
HCA icon
77
HCA Healthcare
HCA
$82B
$2.07M 0.2%
21,300
– –
RARE icon
78
Ultragenyx Pharmaceutical
RARE
$2.87B
$2.06M 0.2%
40,300
-600
-1% -$30.2K
SAGE
79
DELISTED
Sage Therapeutics
SAGE
$2M 0.2%
12,450
-200
-2% -$34K
ICPT
80
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.96M 0.19%
31,900
+12,500
+64% +$753K
MCK icon
81
McKesson
MCK
$97.7B
$1.94M 0.19%
13,800
– –
PEN icon
82
Penumbra
PEN
$12.5B
$1.94M 0.19%
16,800
– –
ITCI
83
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.92M 0.19%
91,000
-1,500
-2% -$29.2K
DVAX
84
DELISTED
Dynavax Technologies
DVAX
$1.88M 0.19%
94,500
+39,500
+72% +$682K
ANGO icon
85
AngioDynamics
ANGO
$558M
$1.75M 0.17%
101,700
– –
EGRX
86
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.74M 0.17%
33,000
– –
NUVA
87
DELISTED
NuVasive, Inc.
NUVA
$1.69M 0.17%
32,312
– –
CHRS icon
88
Coherus Oncology
CHRS
$217M
$1.66M 0.16%
150,000
– –
HCSG icon
89
Healthcare Services Group
HCSG
$1.73B
$1.65M 0.16%
38,000
– –
CLLS
90
Cellectis
CLLS
$268M
$1.64M 0.16%
52,100
+27,750
+114% +$877K
BHC icon
91
Bausch Health
BHC
$1.77B
$1.59M 0.16%
+100,000
New +$1.86M
PODD icon
92
Insulet
PODD
$11.5B
$1.56M 0.15%
18,000
– –
TEVA icon
93
Teva Pharmaceuticals
TEVA
$36.7B
$1.54M 0.15%
90,000
-581,940
-87% -$11.4M
AET
94
DELISTED
Aetna Inc
AET
$1.52M 0.15%
9,000
-13,000
-59% -$2.34M
XENT
95
DELISTED
Intersect ENT, Inc
XENT
$1.51M 0.15%
38,430
– –
MASI
96
DELISTED
Masimo
MASI
$1.5M 0.15%
17,000
– –
HALO icon
97
Halozyme
HALO
$9.21B
$1.49M 0.15%
75,800
-1,200
-2% -$23.2K
IPXL
98
DELISTED
Impax Laboratories, Inc.
IPXL
$1.46M 0.14%
75,000
– –
QTRX icon
99
Quanterix
QTRX
$182M
$1.43M 0.14%
83,800
– –
PTLA
100
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.4M 0.14%
42,700
-650
-1% -$28.5K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.